Skip to main content

Table 1 Characteristics of 55 patients at study entry

From: Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Female n(%)

38 (69.1)

New onset n(%)

48 (87.3)

Age at onset (years) median (IQR)

4.8 (2.2; 10.0)

Age at MTX start (years) median (IQR)

5.3 (2.8; 10.6)

Interval from onset to MTX start (months) median (IQR)

3.8 (2.5; 6.4)

JIA subtype n

  – Oligoarthritis: persistent/extended

18/3 (32.7 %/5.5 %)

  – Polyarthritis (RF positive n = 1)

25 (45.5 %)

  – Systemic with polyarthritis

5 (9.1 %)

  – Enthesitis-related

3 (5.5 %)

  – Psoriatic

1(1.8 %)

Parent/patient global assessment of well-being mm, median (IQR)

27 (15; 40)

CHAQ 0–3 median (IQR)

0.25 (0.13; 0.69)

ESR mm/h median (IQR)

23 (15; 35)

MTX dose mg/m2 /week median (IQR)

14.2 (12.1;15.2)

  – s.c. (n = 45)

14.4 (13.3; 15.9)

  – p.o. (n = 10)

11.7 (8.3; 12.5)

Concomitant therapy n(%)

  – IATHa

21 (38.2)

  – Sulphasalazine

1 (1.8)

  – Systemic corticosteroids

9 (16.4)

  – Folic acid 5–10 mg/weekb

55 (100)

  1. aWithin 1 month prior to or after MTX start
  2. bOnce weekly dose 24–48 hours post-MTX administration
  3. MTX, Methotrexate
  4. IATH, Intraarticular triamcinolone hexacetonide
  5. CHAQ, Childhood Health Assessment Questionnaire
  6. Global assessments in mm on the 100 mm visual analogue scale